Medable: $78m investment in DCT tech
Decentralized trial tech firm Medable has landed $78m USD in funding to help fund its digital and virtual clinical trial solutions. The company reportedy will use the funding further adoption of digital trials and patient-centric strategies at a global scale.
“The shift to patient-centered drug development necessitates entirely new strategies and technologies,” said Michelle Longmire, CEO and co-founder. “Medable is committed to delivering the leading solutions to drug developers for this incredibly important change in how clinical research is conducted; our team is passionate about building a world with ubiquitous research access and radically accelerated drug development timelines.”
